Inflammatory bowel disease: Important to assess, to treat, and to follow correctly, as Dr Anne-Marie Griffiths of Toronto confirmed in an interview recorded in Helsinki at the ESPGHAN annual meeting. She poses for us three questions:

1. What are some of the consequences for the patient when caregivers mislabel the type of inflammatory bowel disease?

2. What purpose is served by thorough diagnostic evaluation at presentation, with upper endoscopy, ileocolonoscopy, and small-bowel imaging?

3. What are the goals to be achieved by using the Paris classification or any of its future modifications?

This discussion addresses those questions, adducing the work in the references below and taking listeners through the evolution of categories of inflammatory bowel disease and their clinical associations.

LiteratureLevine A et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: The Paris classification. Inflamm Bowel Dis 2011 Jun; 17(6):1314-1321. Doi: 10.1002/ibd.21493. Epub 2010 Nov 8. PMID: 21560194

Levine A et al. ESPGHAN revised Porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 2014 Jun; 58(6):795-806. Doi: 10.1097/MPG.0000000000000239. PMID: 24231644

Dhaliwal J et al. Phenotypic variation in paediatric inflammatory bowel disease by age: A multicentre prospective inception cohort study of the Canadian Children IBD Network. J Crohns Colitis 2020 May 21; 14(4):445-454. Doi: 10.1093/ecco-jcc/jjz106. PMID: 31136648. PMCID: PMC7242003

Ledder O et al. Appraisal of the PIBD-classes criteria: A multicentre validation. J Crohns Colitis 2020 Dec 2; 14(12):1672-1679. Doi: 10.1093/ecco-jcc/jjaa103. PMID: 32453831

Dr. Griffith´s favourite song: Allanis Morisette - Hand in my pocket

ESPGHAN favourite Songs can be found on Spotify https://open.spotify.com/playlist/0YIHKjxITLEm9XNyHyypTo